🇺🇸

US SEC Filing Intelligence

· daily

High-Value Federal Grants ($5M+) — April 16, 2026

These 12 high-value federal contracts total $2,556,508,585 in obligations, entirely civilian with 0/12 defense-related, spanning agencies like Department of State, HHS, NASA, USAID, DHS, USDA, DOE, and GSA. Dominant themes include IT facilities management, medical equipment maintenance, aviation support, and space services, with bullish signals from strong outlay execution in maturing awards like AAR Government Services' $449M State contract and Agiliti Health's $327M HHS ventilator maintenance deal. Highest-conviction bullish signal is on Agiliti Health Inc ($326.6M obligation, $272M outlayed, potential to $494M), reflecting HHS preparedness priorities with low execution risk despite firm-fixed pricing. Key risk is high pricing risk from firm-fixed structures in 5+ contracts (e.g., Agiliti, Amentum $227M NASA), vulnerable to cost overruns; watch 2026 contract end-dates like DLH's April 2026 NIH IT award for recompetes.

12 total filings
· daily

DOE Energy Grants — April 16, 2026

The single contract analyzed represents a $67,431,514 total obligation to North Wind Portage, Inc. from the Department of Energy, fully civilian with 0/1 defense-related exposure. Dominant agency theme is DOE Environmental Management's ongoing remediation needs at the Energy Technology Engineering Center in Simi Valley, CA. Highest-conviction signal is neutral steady long-term federal revenue for this small disadvantaged, Alaskan Native Corporation firm, estimated at $5-6 million annually over the 2014-2026 period. Approximately $42.5 million has been outlayed, leaving $25 million in remaining obligation under this firm fixed price delivery order. Key risk is high execution and pricing risk on the fixed-price structure amid the contract's extended performance through April 13, 2026.

1 total filings
· daily

General Federal Contracts — April 16, 2026

These 12 civilian contracts total $2,556,508,585 in obligations with 0 defense-related awards, highlighting steady execution in federal civilian agencies like Department of State ($1.07B across CGI Federal $619.97M and AAR $449.04M), HHS ($433.94M across Agiliti Health $326.62M and DLH $107.32M), and NASA ($327.11M across Amentum $227.20M and Axiom Space $99.91M). Dominant themes include IT/facilities management, medical equipment maintenance, and aviation/space support, with 7 bullish signals driven by high outlays (e.g., Agiliti Health's $272M outlayed on $327M HHS ventilator contract). Highest-conviction bullish signal is AAR Government Services' $449M Department of State aircraft maintenance deal with $290M outlayed and low pricing risk through 2024. Key risk is high firm-fixed-price exposure in 5 contracts (e.g., Agiliti Health, DLH, Amentum), amplifying performance risks amid maturing periods ending 2024-2026; watch outlay progress and recompetes.

12 total filings
· daily

All NASA Contracts — April 16, 2026

NASA awarded $327,111,887 in two civilian contracts during April 16, 2026, with zero defense-related obligations, highlighting ongoing investments in facilities maintenance and space vehicle technology. Dominant themes include long-term facilities support at NASA Ames Research Center via Amentum Technology, Inc. ($227,200,441 obligation) and EVA demonstration capabilities at NASA Johnson Space Center via Axiom Space Inc ($99,911,446 obligation). The highest-conviction signal is bullish for Axiom Space Inc, driven by $77.4M outlays and $71.7M in unexercised options toward a $171.6M ceiling in the space sector. Both contracts carry high firm fixed price execution risks, with Amentum's nearing its 2026-04-12 end date warranting close monitoring for option exercises.

2 total filings
· daily

S&P 500 Technology Sector SEC Filings — April 16, 2026

Across 17 filings in the S&P 500 Technology stream, proxy statements dominate for tech leaders Arista Networks and Salesforce, signaling stable governance with experienced boards focused on AI, cloud, and cybersecurity ahead of May AGMs, while 13Fs from four institutions (Klaas, Paladin, Rockland, First Community) reaffirm $500M+ collective exposure to mega-tech (NVDA $11.8M total, AAPL $73.8M+, MSFT $9.9M+, GOOG $132M+, AMAT $9.8M) as of Q1 2026 end, indicating sustained institutional conviction amid no disclosed QoQ changes. Non-tech context filings highlight routine capital activities (e.g., dividend adjustments, share authorizations) with neutral sentiment overall, but mixed signals like abrdn VFL's junk muni policy shift to 100% exposure and Texas Bancshares' loan deteriorations underscore credit risks outside core tech. No explicit YoY/QoQ financial trends in proxies/13Fs, but forward-looking AGMs (May-June 2026) and special meetings build a catalyst calendar; capital allocation leans conservative with maintained dividends and no buybacks noted. Sector implications favor big tech stability via 13F holdings, with Arista/Salesforce governance votes as near-term events, though dilution risks from share increases (Altimmune +400M shares) warrant caution. Portfolio-level pattern: 4/17 filings (tech proxies + 13Fs) drive bullish tech overweight, contrasting neutral/mixed non-core.

6 high priority 11 medium 17 total filings
· daily

Nasdaq 100 Stocks SEC Filings — April 16, 2026

Across 21 filings from NASDAQ-100 related entities, dominant themes include robust Q1 2026 earnings beats from blue-chips like PepsiCo (revenue +8.5% YoY to $19.4B, OP +24%, EPS +27%) and Netflix (revenue +16% YoY to $12.3B, OP margin +60bps to 32.3%), affirming FY guidance amid volume headwinds and content spend pressures. Proxy statements (Meta, Netflix, Immunocore, Texas Community) highlight governance focus with upcoming AGMs in May-June 2026, director elections, and shareholder proposals on AI, pay, ESG. Capital allocation shines with PepsiCo's 54th consecutive dividend hike (+4%) and Community Bancorp's $0.25/share quarterly payout, while financings bolster EV/battery plays (Faraday Future +$2M to $12M investment, International Battery $2.8M insider-led). Mixed sentiments prevail in 7/21 filings, driven by volume declines (Pepsi organic -3%), rising debt (Pepsi short-term x2), and riskier policies (abrdn junk bonds to 100% assets). Portfolio-level trends show consumer giants outpacing with 12-24% OP growth vs. modest cash flows, signaling reinvestment over returns; no broad insider selling patterns, but director retirements neutral. Implications: Bullish for staples/streaming stability, watch governance votes and May catalysts for volatility.

9 high priority 12 medium 21 total filings
· daily

S&P 500 Financials Sector SEC Filings — April 16, 2026

Across 50 SEC filings from S&P 500 Financials and related entities (banks, insurers, asset managers, services), sentiment is predominantly mixed (24/50), with positive outliers in revenue growth (e.g., avg +15-30% YoY in TSMC +31.6%, Bilibili +13.1%, KeyCorp NII +11%) but persistent net losses widening/narrowing unevenly (e.g., Capstone loss +728%, Ionetix +32%). Banks like First Financial Bancorp and Cathay General Bancorp highlight M&A (Westfield/BankFinancial acquisitions) and strong 2025 performance, while asset managers (Brookfield, abrdn) pursue debt raises and policy shifts for yield. Capital allocation trends favor shareholder returns (KeyCorp $389M buybacks, News Corp $1B program, PepsiCo 4% dividend hike), with 12+ companies announcing dividends/buybacks/splits. Proxy season intensifies with 15+ AGMs May-June 2026 (e.g., Cohen & Co June 3, Glaukos May 28), signaling governance catalysts. Forward-looking data flags divestitures (CareDx Q3 2026 close), earnings (Corebridge May 4/5), and guidance (PepsiCo FY2026 organic 2-4%). Portfolio-level: Revenue resilient (+ avg 10% YoY in 20 reporters) but op margins volatile (-150bps avg compression in 8/10 mixed cos), implying selective opportunities in banks amid sector rotation.

30 high priority 20 medium 50 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — April 16, 2026

Across 50 filings dated April 16, 2026, proxy statements dominate (e.g., DEF 14A/DEFA14A for Excelerate Energy, Stellus entities, Glaukos, Korro Bio, Colgate-Palmolive, Clearway), signaling peak proxy season with neutral sentiment and upcoming AGMs in May-June 2026. Q1 2026 earnings reveal resilient profits amid revenue softness: PepsiCo revenue +8.5% YoY/organic +2.6% but volumes -3%; Travelers NI +333% YoY on lower cat losses; Marsh & McLennan revenue +8% but GAAP income -12% on litigation charge. Consumer Staples highlights include PepsiCo affirming FY2026 organic revenue 2-4%/EPS 4-6% growth with 4% dividend hike (54th consecutive), while CCEP and Colgate prep neutral AGMs. Capital allocation trends strong with $2.2B shareholder returns at Travelers, $755M buybacks at Marsh; margin compression evident in industrials (Lakeland -820bps YoY). Portfolio-level patterns show 7/12 earnings reporters with YoY profit growth >20% despite mixed volumes/pricing, bullish advisor upgrades (Stellus/Ridgepost $43B AUM), but covenant waivers (Katapult 10th) flag credit risks. Implications: Favor staples dividend payers like PEP/CL amid volatility; monitor May earnings catalysts for guidance updates.

18 high priority 32 medium 50 total filings
· daily

S&P 500 Industrials Sector SEC Filings — April 16, 2026

The 50 filings for USA S&P 500 Industrials stream reveal a skew toward financials/banks (e.g., US Bancorp, BNY, Bank First) showing robust YoY revenue/NII growth averaging ~15-20% (US Bancorp +4.7%, BNY +13%, Bank First NII +45.8%) driven by acquisitions and partnerships, though QoQ declines (e.g., US Bancorp -1%, BNY Investment/Wealth -3%) signal seasonal softness and margin pressures (Bank First NIM -1.2% QoQ). Proxy statements dominate (20+ filings) heralding AGM season May-June 2026 with director elections and say-on-pay votes, mostly neutral. Operating companies mixed: revenue growth in Ionetix +67.7% YoY but wider losses, SurgePays -6% YoY with equity deficit -$15.4M; narrowing losses in Catalyst Crew -95% op ex drop, Brand Engagement +176% rev. Capital allocation favors shareholders via dividend hikes (Bank First +22.2% YoY, First Interstate $311.9M returns =103% NI) and buybacks. Debt refinancings/raises positive (Herbalife $800M, Lincoln Educational to $125M). 13Fs show big tech concentration (NVIDIA/MSFT/AAPL top across AEGON, Sander, etc.). Portfolio implication: overweight banks with NII momentum, monitor May earnings for guidance amid acquisition integrations.

18 high priority 32 medium 50 total filings
· daily

S&P 500 Energy Sector SEC Filings — April 16, 2026

Hooker Furnishings (the sole filing in this S&P 500 Energy stream snapshot) reported fiscal 2026 results marked by revenue declines of 12.4% YoY to $278.1M and 20.5% YoY in Q4 to $67.0M, driven by shorter quarter, lower hospitality shipments, and weather disruptions, yet demonstrated robust cost discipline with $26.3M in fixed cost cuts, $11.9M SG&A reduction, and 180 bps gross margin expansion. Full-year operating loss of $16.5M was largely due to $15.6M non-cash impairments, partially offset by positive Q4 operating income of $0.6M. The company completed divestitures of Pulaski Furniture and Samuel Lawrence Furniture, authorized a $5M share repurchase program, and adjusted its annual dividend to $0.46 per share, signaling focus on core operations and shareholder returns. Liquidity strengthened post-year-end to $12M cash and $64.1M available borrowing capacity as of April 15, 2026, with no credit facility balance. Mixed sentiment reflects revenue weakness balanced by efficiency gains, positioning Hooker as a potential turnaround amid sector scrutiny. Key implication: Cost savings of $17.5M tied to continuing operations could drive profitability recovery if sales stabilize.

1 medium 1 total filings
· daily

US Material Events SEC 8-K Filings — April 16, 2026

Across 50 SEC filings from April 16, 2026, dominant themes include widespread executive transitions (22+ appointments/resignations, mostly positive in biotech/pharma/fintech), robust capital raises ($1B+ TeraWulf, $463M Spyre, $354M Achieve Life), and credit facility expansions (Lincoln Edu to $125M, ICF $1.45B total), signaling growth funding amid strong revenue trends like CareDx +39% YoY total revenue and Ionetix +67.7% FY2025 revenue. Mixed financial health evident with outliers like Katapult's 10th covenant waiver and Ionetix's 32% YoY wider net loss/94.6% cash drop raising going concern risks, contrasted by positive divestitures (CareDx $170M Lab Products sale) and M&A (MeiraGTx $25M J&J asset buy). Neutral governance events (annual meetings, board changes) dominate non-material filings, with biotech/pharma showing 8/12 positive sentiments tied to pipeline advances and financings. Portfolio-level trends: Revenue growth in 4/50 (avg +48% YoY in healthcare), but profitability pressures (Ionetix op ex +17% YoY); capital allocation favors equity/debt raises over buybacks/dividends. Implications: Bullish for growth-oriented small/mid-caps in biotech/energy, cautious on stressed lenders like Katapult; watch Q2 catalysts like FDA dates and annual meetings for alpha.

50 high priority 50 total filings
· daily

Dow Jones 30 Stocks SEC Filings — April 16, 2026

Across the 50 SEC filings from the USA Dow Jones 30 intelligence stream (primarily financials, insurers, and related blue-chips, with some small-caps), Q1 2026 earnings dominate, revealing strong YoY net income growth averaging +100% in key financials (Travelers +333%, BNY +42% EPS, US Bancorp +13.8%, BancFirst +12.3%, Bank First +9.9%) driven by lower catastrophe losses, NII expansion (Bank First +45.8% YoY), and fee growth, though QoQ dips (-4.9% NI US Bancorp), premium declines (Travelers -2% NWP), and NIM compression (Bank First -1.2% QoQ) signal moderating momentum. Capital allocation remains shareholder-friendly with dividend increases (Travelers +14% to $1.25, Bank First +22.2% YoY to $0.55) and buybacks ($2.223B Travelers Q1, $1.8B 10-Q). Small-caps show distress patterns: revenue drops (Hooker -20.5% Q4, Vipshop -2.3% FY), net losses, dilution risks (RenovoRx 16M shares), auditor changes (LanzaTech), and filing delays (CETI, AMC). Biotech highlights include MeiraGTx positive 3-yr clinical data (17-pt XQ improvement) and J&J asset buy ($25M upfront). Over 15 proxy filings cluster AGMs in May-Jun 2026 as near-term catalysts, with neutral sentiment but positive exec comp approvals. Portfolio-level: Financials outperform (ROE 19.7% Travelers), but watch margin trends and small-cap liquidity; actionable buy dips in strong capital returners.

26 high priority 24 medium 50 total filings
· daily

US SEC Filings Daily Market Digest — April 16, 2026

Across 50 SEC filings for April 16, 2026, mixed sentiments dominate with 18 mixed, 6 positive, 5 negative, and others neutral, reflecting resilient revenue growth in semiconductors (TSMC +31.6% YoY) and consumer giants (PepsiCo +8.5% YoY) offset by widening losses in small caps (e.g., Capstone net loss +728%, Ionetix -32%). Period-over-period trends show 12/20 annual reports with revenue growth averaging +45% YoY in outperformers like NextNRG (+195%) but declines in 8/20 (avg -20% YoY), margin expansions in TSMC (+ to 59.9%) contrasting compressions elsewhere. Capital allocation leans shareholder-friendly with buybacks (Hooker $5M, News Corp $1B program), dividend hikes (PepsiCo +4%, 54th year), and M&A/divestitures (CareDx $170M sale, First Financial acquisitions). Proxy season ramps up with 10+ AGMs in May-June 2026, signaling governance focus amid strong bank performance. Debt raises (Brookfield $1B notes, Herbalife $800M) indicate liquidity bolstering, but going concern doubts in 5 small caps highlight microcap risks. Portfolio implication: Favor large-cap growth (tech/consumer) over volatile small caps; monitor Q1 earnings catalysts.

28 high priority 22 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — April 16, 2026

Across 50 filings from the S&P 500 Consumer Discretionary stream (broadly including retail, autos, and adjacent financials/REITs), proxy statements dominate (20+ DEF/DEFA14A) signaling annual meeting season with positive comp trends in Yum China (STI 216% payout) and Life360 (32% revenue growth), while Q1 2026 earnings reveal mixed financial performance: banks like Citizens Financial (+39% YoY NI), BancFirst (+12.3%), and Bank First (+9.9%) show robust NII growth (avg +22% YoY) post-acquisitions but NIM compression (-24 bps to -120 bps QoQ); consumer names like Hooker Furnishings report sales declines (-20.5% Q4 YoY) and impairments ($15.6M). Key trends include revenue acceleration in high-performers (TSMC +31.6% YoY, Life360 +32%) vs declines (Hooker FY -12.4%, N2OFF op loss +29%), dividend hikes (Bank First +22.2% YoY, Four Corners +3.2%), and capital raises/debt refinancings (TeraWulf $1.03B equity, Herbalife $800M notes). Critical developments: guidance cuts (Knight-Swift Q1 EPS slashed 70%), Nasdaq risks (Fathom, Smith Micro), and liquidations (NLOP portfolio down to 18 properties); implications favor financials for stability, caution retail amid weather/M&A costs, with catalysts in May/June meetings.

22 high priority 28 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — April 16, 2026

Across 50 filings in the USA S&P 500 Healthcare intelligence stream (with broader financial crossovers), dominant themes include robust YoY Q1 2026 earnings growth in banks (avg +30% net income across Citizens, KeyCorp, BNY) contrasting QoQ softness (-2-3% revenue), a biotech funding surge (Achieve $354M, Revolution $1.65B equity +$500M notes, Alamar revenue +195% YoY), and 20+ 13F-HR filings revealing institutional portfolios overloaded with S&P 500 ETFs (e.g., iShares/Vanguard dominating 50-80% allocations) and megacap tech (Apple/NVIDIA top holdings). Healthcare-specific trends show Abbott's comparable sales +3.7% YoY but Nutrition decline -7.7% and Diagnostics weakness, offset by Exact Sciences M&A; operational metrics like Alamar's gross profit +385% YoY highlight proteomics growth outliers. Capital allocation leans shareholder-friendly with bank dividends steady ($0.46 Citizens, $0.17 South Plains) and buybacks (KeyCorp $389M, News Corp $1B program), while forward-looking catalysts cluster in May-Jun (earnings, AGMs, PDUFA). Portfolio-level patterns flag financial resilience amid rate pressures (NIM +24bps Citizens), biotech conviction via raises/appointments (Prime Medicine new CFO, Achieve new CEO), but risks in zero-revenue entities (Catalyst Crew) and cash flow swings (Grupo Galicia). Overall, actionable tilt to biotech catalysts and bank dividend stability, with 13Fs signaling passive rotation into broad indices.

12 high priority 38 medium 50 total filings
· daily

US Executive Compensation Proxy SEC Filings — April 16, 2026

Across 50 DEF 14A proxy statements filed primarily on April 16, 2026, for 2026 annual meetings (mostly May-June), companies emphasize 2025 performance to support advisory 'say-on-pay' votes, with 15+ filings highlighting YoY revenue growth averaging 25-35% in tech/biotech (e.g., Roblox +36%, Axon +33%, Life360 +32%) and steady FFO/AFFO gains in REITs (Four Corners FFO +$0.03 YoY). Financials dominate (20+ banks/BDCs) with branch optimizations, mergers (Mechanics Bancorp 91.7% owned post-merger), and capital returns (First Interstate $311.9M or 103% of NI via divs/buybacks). Positive sentiment in 12 filings tied to OP growth (Yum China +11%), backlog builds (Valaris $2.6B), and advisor upgrades (Stellus/Ridgepost $43B AUM); mixed/neutral in most due to dilution risks from equity plan expansions (e.g., Cohen +80% shares). Portfolio trends show margin expansion in high-performers (Life360 EBITDA margin +700bps to 19%) vs compression in others (Docusign GAAP EPS -71%), signaling sector rotation to growth tech/healthcare amid financial stability. Key implications: High exec equity alignment boosts conviction, but 25+ seek share increases signaling dilution (avg +20-100%); monitor mid-2026 advisor closings and June liquidations for catalysts.

50 high priority 50 total filings
· daily

US IPO Pipeline SEC S-1 Filings — April 16, 2026

The IPO Pipeline stream features 5 new S-1 filings (OLB Group, Disciplined Growth Acquisition, VisionWave Holdings, EagleRock Land, Luvulis Corp) and 1 S-4 (Qwest Corp), highlighting a surge in microcap IPOs/SPACs amid high-risk profiles and one telecom debt restructuring. EagleRock Land stands out with explosive YoY growth: revenues +308% to $72.2M, Adjusted EBITDA +383% to $35.5M, and acreage +59% to 193,875, though net losses widened from $1.1M to $73.1M due to expansion costs. Common themes include neutral-to-negative sentiments (1 neutral, 4 mixed, 1 negative), heavy risk disclosures (going concern doubts, dilution, low liquidity), no dividends across all, and limited forward-looking guidance beyond deal timelines. Qwest's $5.75B asset sale enabled $4.8B deleveraging but higher-cost refinancing signals mixed capital allocation. Portfolio-level trends show 1/6 with hyper-growth (energy services outlier), while 5/6 are pre-revenue or resale-focused with penny stock volatility. Market implications favor monitoring EagleRock for Permian water infrastructure catalysts but caution on dilution-heavy resales and SPAC redemption risks.

6 high priority 6 total filings
· daily

Global High-Priority Regulatory Events — April 16, 2026

Across 50 filings in the 'Global High Priority Market Events' stream, proxy statements dominate (e.g., Arbor Realty, Excelerate Energy, Immunocore, Smith Micro, multiple bancorps) signaling peak 2026 AGM season with director elections, equity plans, and say-on-pay votes clustered in May-June. Financial trends show robust revenue growth in large caps like TSMC (+31.6% YoY to NT$3.8T, margins to 59.9%), PepsiCo (+8.6% YoY Q1 to $19.4B, OP +24.4%), Bilibili (+13.1% YoY to RMB30.3B with profit swing), but microcaps exhibit persistent losses narrowing (e.g., SEATech -75% YoY, Catalyst Crew -95% op ex) amid zero revenue and going concern doubts (Horizon Quantum, Ionetix, Data443). M&A/divestitures active: ESCO acquiring Megger ($1.5B financing), CareDx divesting Lab Products ($170M cash), Qwest debt exchange to simplify structure post-$5.75B asset sale. Indian filings highlight distress (AYM Syntex amalgamations, Future Consumer insolvency hearing, open offers at premiums). Capital allocation leans to deleveraging (Lumen/Qwest repaid $4.8B debt) and liquidity boosts (Lincoln Ed $125M facility). Portfolio-level: 12/25 with PoP data show avg revenue +15% YoY but mixed profitability; sector outliers in semis/consumer bullish, small caps bearish. Implications: Near-term catalysts from May meetings could drive volatility; favor large-cap growth over microcap risks.

50 high priority 50 total filings
· daily

US Earnings Financial Results SEC Filings — April 16, 2026

Across 32 filings primarily covering FY2025 10-Ks and Q1 2026 10-Qs, sentiment is overwhelmingly mixed (25/32), with microcap/development-stage firms (e.g., SEATech, JOCOM, Catalyst Crew) showing narrowed losses via expense cuts (avg ~70% improvement in 8 cases) but persistent zero revenue and going concern risks, while larger caps like PepsiCo (+8.6% revenue YoY), Fastenal (+12.4%), and Travelers (+333% net income) drove positive trends. Portfolio-level, revenue grew in 12/32 (avg +20% YoY where positive), but declined in 14 (avg -40%), with gross margins compressing in 10/32 (avg -200bps, e.g., Lakeland -820bps). Acquisitions/share issuances boosted assets in 15 firms (avg +100% YoY), but cash burn persists in 20+, offset by financing. Capital allocation leans toward buybacks/dividends in stables (Travelers $1.8B buyback, Fastenal dividend +12%), signaling conviction, while microcaps dilute via issuances. Key implication: Opportunities in turnaround microcaps narrowing losses and established consumer/insurance names, but watch margin pressures and working capital deficits amid 2026 economic uncertainty.

32 high priority 32 total filings
· daily

US SEC Trading Suspension Halt Orders — April 16, 2026

The single filing in the USA Trading Suspensions stream highlights a critical Nasdaq compliance deficiency for Fathom Holdings Inc. (FTHM), with its bid price below $1.00 for 30 consecutive business days as of April 10, 2026, violating Listing Rule 5550(a)(2). No period-over-period financial trends, insider activity, capital allocation, or forward-looking guidance beyond compliance are detailed in the enriched data, limiting quantitative comparisons across companies. The negative sentiment (9/10 materiality) signals heightened delisting risk, with 180 days until October 7, 2026, to regain a $1.00+ bid for 10 consecutive days under Rule 5810(c)(3)(A). Failure could trigger delisting, though a second 180-day period is possible if other Capital Market standards are met. This isolated event underscores small-cap vulnerability to regulatory halts amid potential sector weakness, with no immediate listing impact but evaluating options like reverse stock split. Portfolio implications point to monitoring similar bid-price deficient names for cascading suspension risks.

1 high priority 1 total filings